Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wolters-kluwer-health/a-dual-color-immunohistochemistry-assay-for-measurement-of-cereblon-in-ISlbQKRKKF
References (34)
-
O. Cope, S. Wyman (1948)
Multiple myeloma.The New England journal of medicine, 239 10
-
(GandhiAKKangJHavensCG Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN). Br J Haematol. 2014;164:811–821.24328678)
GandhiAKKangJHavensCG Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN). Br J Haematol. 2014;164:811–821.24328678, GandhiAKKangJHavensCG Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN). Br J Haematol. 2014;164:811–821.24328678
-
A. Gandhi, D. Mendy, M. Waldman, Gengxi Chen, E. Rychak, Karen Miller, S. Gaidarova, Y. Ren, Maria Wang, M. Breider, G. Carmel, Afshin Mahmoudi, P. Jackson, M. Abbasian, B. Cathers, P. Schafer, Thomas Daniel, A. López-Girona, A. Thakurta, R. Chopra (2013)
Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexityBritish Journal of Haematology, 164
-
Takumi Ito, H. Ando, Takayuki Suzuki, T. Ogura, K. Hotta, Yoshimasa Imamura, Y. Yamaguchi, H. Handa (2010)
Identification of a Primary Target of Thalidomide TeratogenicityScience, 327
-
D. Heintel, A. Rocci, H. Ludwig, A. Bolomsky, S. Caltagirone, M. Schreder, S. Pfeifer, H. Gisslinger, N. Zojer, U. Jäger, A. Palumbo (2013)
High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasoneBritish Journal of Haematology, 161
-
National Cancer Institute. Requirements for pharmacokinetic and biomarker methods development -
S. Schuster, K. Kortuem, Yuan-Xiao Zhu, E. Braggio, C. Shi, L. Bruins, Jessica Schmidt, G. Ahmann, Shaji Kumar, S. Rajkumar, J. Mikhael, B. Laplant, Mia Champion, K. Laumann, B. Barlogie, R. Fonseca, P. Bergsagel, M. Lacy, A. Stewart (2014)
The clinical significance of cereblon expression in multiple myeloma.Leukemia research, 38 1
-
(HuangSYLinCWLinHH Expression of cereblon protein assessed by immunohistochemical staining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma. Ann Hematol. 2014;93:1371–1380.24687382)
HuangSYLinCWLinHH Expression of cereblon protein assessed by immunohistochemical staining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma. Ann Hematol. 2014;93:1371–1380.24687382, HuangSYLinCWLinHH Expression of cereblon protein assessed by immunohistochemical staining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma. Ann Hematol. 2014;93:1371–1380.24687382
-
(Lopez-GironaAMendyDItoT Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26:2326–2335.22552008)
Lopez-GironaAMendyDItoT Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26:2326–2335.22552008, Lopez-GironaAMendyDItoT Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26:2326–2335.22552008
-
K. Mccarty, L. Miller, E. Cox, J. Konrath, K. Mccarty (1985)
Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies.Archives of pathology & laboratory medicine, 109 8
-
A. Broyl, R. Kuiper, M. Duin, B. Holt, Laila Jarari, U. Bertsch, S. Zweegman, A. Buijs, D. Hose, H. Lokhorst, H. Goldschmidt, P. Sonneveld (2013)
High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance.Blood, 121 4
-
(National Cancer Institute. Requirements for pharmacokinetic and biomarker methods development. 1999. Available at: http://prevention.cancer.gov/files/clinical-trials/biomarkers.pdf. Accessed March 20, 2014.)
National Cancer Institute. Requirements for pharmacokinetic and biomarker methods development. 1999. Available at: http://prevention.cancer.gov/files/clinical-trials/biomarkers.pdf. Accessed March 20, 2014., National Cancer Institute. Requirements for pharmacokinetic and biomarker methods development. 1999. Available at: http://prevention.cancer.gov/files/clinical-trials/biomarkers.pdf. Accessed March 20, 2014.
-
(HeintelDRocciALudwigH High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Br J Haematol. 2013;161:695–700.23565715)
HeintelDRocciALudwigH High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Br J Haematol. 2013;161:695–700.23565715, HeintelDRocciALudwigH High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Br J Haematol. 2013;161:695–700.23565715
-
(SchusterSRKortuemKMZhuYX The clinical significance of cereblon expression in multiple myeloma. Leuk Res. 2014;38:23–28.24129344)
SchusterSRKortuemKMZhuYX The clinical significance of cereblon expression in multiple myeloma. Leuk Res. 2014;38:23–28.24129344, SchusterSRKortuemKMZhuYX The clinical significance of cereblon expression in multiple myeloma. Leuk Res. 2014;38:23–28.24129344
-
(McCartyKSJrMillerLSCoxEB Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109:716–721.3893381)
McCartyKSJrMillerLSCoxEB Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109:716–721.3893381, McCartyKSJrMillerLSCoxEB Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109:716–721.3893381
-
(KronkeJUdeshiNDNarlaA Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science (New York, N Y). 2014;343:301–305.)
KronkeJUdeshiNDNarlaA Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science (New York, N Y). 2014;343:301–305., KronkeJUdeshiNDNarlaA Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science (New York, N Y). 2014;343:301–305.
-
A. Seshire, T. Rößiger, M. Frech, S. Beez, H. Hagemeyer, E. Puccetti (2012)
Direct interaction of PU.1 with oncogenic transcription factors reduces its serine phosphorylation and promoter bindingLeukemia, 26
-
(ZhuYXBraggioEShiCX Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011;118:4771–4779.21860026)
ZhuYXBraggioEShiCX Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011;118:4771–4779.21860026, ZhuYXBraggioEShiCX Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011;118:4771–4779.21860026
-
(Guidelines for industry, text on validation of analytical procedures. ICH-Q2A, 1995. Available at: http://www.labcompliance.de/documents/international/ich/h-307-ich-fda-methods-terminology-ichq2a.pdf. Accessed March 20, 2014.)
Guidelines for industry, text on validation of analytical procedures. ICH-Q2A, 1995. Available at: http://www.labcompliance.de/documents/international/ich/h-307-ich-fda-methods-terminology-ichq2a.pdf. Accessed March 20, 2014., Guidelines for industry, text on validation of analytical procedures. ICH-Q2A, 1995. Available at: http://www.labcompliance.de/documents/international/ich/h-307-ich-fda-methods-terminology-ichq2a.pdf. Accessed March 20, 2014.
-
A. Gandhi, Jian Kang, Courtney Havens, Thomas Conklin, Yuhong Ning, Lei Wu, Takumi Ito, H. Ando, M. Waldman, A. Thakurta, A. Klippel, H. Handa, Thomas Daniel, P. Schafer, R. Chopra (2013)
Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBNBritish Journal of Haematology, 164
-
(LuGMiddletonRESunH The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science (New York, N Y). 2014;343:305–309.)
LuGMiddletonRESunH The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science (New York, N Y). 2014;343:305–309., LuGMiddletonRESunH The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science (New York, N Y). 2014;343:305–309.
-
(KlimowiczANeriPBelchA High cereblon protein expression correlates with improved response and survival in myeloma patients treated with lenalidomide. Blood. 2012;120:931. [Abstract].)
KlimowiczANeriPBelchA High cereblon protein expression correlates with improved response and survival in myeloma patients treated with lenalidomide. Blood. 2012;120:931. [Abstract]., KlimowiczANeriPBelchA High cereblon protein expression correlates with improved response and survival in myeloma patients treated with lenalidomide. Blood. 2012;120:931. [Abstract].
-
(GandhiAKMendyDWaldmanM Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. Br J Haematol. 2014;164:233–244.24206017)
GandhiAKMendyDWaldmanM Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. Br J Haematol. 2014;164:233–244.24206017, GandhiAKMendyDWaldmanM Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. Br J Haematol. 2014;164:233–244.24206017
-
Shaji Kumar, S. Rajkumar, A. Dispenzieri, M. Lacy, S. Hayman, F. Buadi, S. Zeldenrust, D. Dingli, S. Russell, J. Lust, P. Greipp, R. Kyle, M. Gertz (2008)
Improved survival in multiple myeloma and the impact of novel therapies.Blood, 111 5
-
(KumarSKRajkumarSVDispenzieriA Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–2520.17975015)
KumarSKRajkumarSVDispenzieriA Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–2520.17975015, KumarSKRajkumarSVDispenzieriA Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–2520.17975015
-
(PalumboAAndersonK Multiple myeloma. N Engl J Med. 2011;364:1046–1060.21410373)
PalumboAAndersonK Multiple myeloma. N Engl J Med. 2011;364:1046–1060.21410373, PalumboAAndersonK Multiple myeloma. N Engl J Med. 2011;364:1046–1060.21410373
-
G. Lu, R. Middleton, Huahang Sun, MarkVic Naniong, Christopher Ott, C. Mitsiades, Kwok-kin Wong, J. Bradner, W. Kaelin (2014)
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros ProteinsScience, 343
-
Guidelines for industry, text on validation of analytical procedures. ICH-Q2A -
A. Klimowicz, P. Neri, A. Belch, M. Dean, Li Ren, K. Gratton, J. Slabý, Jordan Johnson, P. Duggan, D. Stewart, N. Bahlis (2012)
High Cereblon Protein Expression Correlates with Improved Response and Survival in Myeloma Patients Treated with LenalidomideBlood, 120
-
Yuan-Xiao Zhu, E. Braggio, C. Shi, L. Bruins, Jessica Schmidt, S. Wier, X. Chang, C. Bjorklund, R. Fonseca, P. Bergsagel, R. Orlowski, A. Stewart (2011)
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.Blood, 118 18
-
Shang‐Yi Huang, Chung-Wu Lin, Hsiu-Hsia Lin, M. Yao, Jih-Luh Tang, Shang-Ju Wu, Yao-chang Chen, H. Lu, H. Hou, Chien-Yuan Chen, W. Chou, W. Tsay, Sheng-Je Chou, H. Tien (2014)
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myelomaAnnals of Hematology, 93
-
J. Krönke, N. Udeshi, A. Narla, Peter Grauman, Slater Hurst, M. McConkey, Tanya Svinkina, D. Heckl, Eamon Comer, Xiaoyu Li, Christie Ciarlo, Emily Hartman, N. Munshi, M. Schenone, S. Schreiber, S. Carr, B. Ebert (2014)
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma CellsScience, 343
-
(BroylAKuiperRvanDM High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood. 2013;121:624–627.23233657)
BroylAKuiperRvanDM High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood. 2013;121:624–627.23233657, BroylAKuiperRvanDM High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood. 2013;121:624–627.23233657
-
(ItoTAndoHSuzukiT Identification of a primary target of thalidomide teratogenicity. Science (New York, N Y). 2010;327:1345–1350.)
ItoTAndoHSuzukiT Identification of a primary target of thalidomide teratogenicity. Science (New York, N Y). 2010;327:1345–1350., ItoTAndoHSuzukiT Identification of a primary target of thalidomide teratogenicity. Science (New York, N Y). 2010;327:1345–1350.
- Copyright
- Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
- ISSN
- 1541-2016
- DOI
- 10.1097/PAI.0000000000000246
- pmid
- 26186254
- Publisher site
- See Article on Publisher Site
Abstract
RESEARCH ARTICLE A Dual Color Immunohistochemistry Assay for Measurement of Cereblon in Multiple Myeloma Patient Samples Yan Ren, MD, MS,* Maria Wang, MD, PhD,* Suzana Couto, DVM, PhD,* Donna E. Hansel, MD, PhD,*w Karen Miller, BS,z Antonia Lopez-Girona, PhD,z Chad C. Bjorklund, PhD,y Anita K. Gandhi, PhD,y Anjan Thakurta, PhD,y Rajesh Chopra, MD, PhD,y and Michael Breider, DVM, PhD* single IHC assay using a published commercial rabbit poly- Abstract: Clinical interest in the measurement of Cereblon clonal Cereblon antibody and could be used to explore the po- (CRBN), the primary target of the IMiDs immunomodulatory tential utility of Cereblon as a biomarker in the clinic. drugs lenalidomide and pomalidomide, has been fueled by its Key Words: immunomodulatory drugs, dual, cereblon, myelo- essential requirement for antitumor or immunomodulatory ac- ma, immunohistochemistry tivity of both drugs in multiple myeloma (MM). However, limited analyses of clinical samples for CRBN gene expression (Appl Immunohistochem Mol Morphol 2015;00:000–000) or protein levels have utilized unvalidated reagents and assays, raising uncertainty about the interpretation of these results. We previously described a highly specific rabbit monoclonal anti- body CRBN65 against 65-76 AA of human Cereblon. Here we reatment with thalidomide and IMiDs immuno- describe a validated dual
Journal
Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health
Published: Jul 1, 2015